CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Rituximab +4 moredrug
Likely dose
Rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00169156
NCT00169156Phase 2Completed
CompareCT.gov

Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).

Lymphoma Study Association·interventional·Posted Sep 15, 2005·Updated Mar 13, 2017

In Brief

A Phase 2 clinical trial evaluating Rituximab, Prednisone, and 3 other interventions for Untreated T-cell Angioimmunoblastic Lymphoma. Completed, enrolled 27 participants across 4 sites.

Detailed Summary

To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUntreated T-cell Angioimmunoblastic Lymphoma
CountriesFrance
CollaboratorsHoffmann-La Roche

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2008
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.8 years ago

Interventions

Rituximabdrug

375 mg/m2 D1

Prednisonedrug

40 mg/m2 D1 to D5

Doxorubicinedrug

50 mg/m2 D1

Cyclophosphamidedrug

750 mg/m2 D1

Vincristinedrug

1,4 mg/m2 D1